Netarsudil and latanoprost combo useful fixed dose option for open-angle glaucoma and IOP: Study

The most common treatment-related adverse events were conjunctival hyperemia and cornea verticillata, where NET/LAT showed slightly higher rates of conjunctival hyperemia when compared to BIM/TIM. Further, these adverse events were consistent with previous findings and did not pose significant safety concerns.

This research emphasized the significance of the findings by stating that once-daily NET/LAT provides a compelling alternative to the fixed-dose combination treatment option for patients with OAG and OHT. This study offers valuable insights into the efficacy and safety profile of NET/LAT that expands the treatment options for individuals with these sight-threatening conditions.

Reference:

Stalmans, I., Lim, K. S., Oddone, F., Fichtl, M., Belda, J. I., Hommer, A., Laganovska, G., Schweitzer, C., Voykov, B., Zarnowski, T., & Holló, G. (2023). MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. In Graefe’s Archive for Clinical and Experimental Ophthalmology (Vol. 262, Issue 1, pp. 179–190). Springer Science and Business Media LLC. https://doi.org/10.1007/s00417-023-06192-0